Eiger Biopharmaceuticals Inc.

Publication describes high level of synergy of clemizole with protease inhibitor class

Publication describes key domain essential for HCV replication and basis for new small molecule inhibitors

PALO ALTO, California, July 1, 2010 - Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the lab of Stanford scientist and Eiger Founder, Dr.

MORE..

Older News

PALO ALTO, California, January 20 - Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the labs of Stanford scientist and Eiger Founder, Dr.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy